PDF(Pubmed)
Abstract：
The antioxidant L-Carnosine is reported to improve negative and cognitive symptoms in Schizophrenia. A randomized double-blind placebo-controlled study was planned to study the effectiveness of adjuvant L-Carnosine therapy in patients with Schizophrenia. 100 eligible patients with predominant negative symptoms as measured by scale for assessment of negative symptoms (SANS total score ≥ 60) and Schizophrenia diagnosis (International Classification of Disorder-Tenth Edition, ICD-10) were recruited. They were randomly allocated to receive a fixed dose of either 400 mg L-Carnosine or identical placebo for 3 months and increased to 800 mg from 13th week till completion of study. Primary outcome measures assessed changes in SANS scores with L-Carnosine at 24 weeks compared to baseline, 4 and 12 weeks. Secondary outcome measures were done to assess the improvement in cognitive symptoms (executive function, attention, and memory) at 24 weeks using subtests of NIMHANS (National Institute for Mental Health and Neurosciences) cognitive battery. Side effects were assessed using adverse events reporting form. The attention scores (p = .023) showed significant differences in patients receiving 800 mg of L-Carnosine at the end of the study. There were no significant differences in negative symptoms in the two arms at study completion. L-Carnosine dosing of 800 mg may be a promising agent to enhance executive functions in Schizophrenia.
摘要：
据报道，抗氧化剂L-肌肽可改善精神分裂症的阴性和认知症状。计划进行一项随机双盲安慰剂对照研究，以研究精神分裂症患者辅助L-肌肽治疗的有效性。通过阴性症状评估量表（SANS总分≥60）和精神分裂症诊断（国际疾病分类-第十版，ICD-10）被招募。他们被随机分配接受固定剂量的400mgL-肌肽或相同的安慰剂3个月，从第13周增加到800mg，直到研究完成。主要结果指标评估了与基线相比，24周时使用L-肌肽的SANS评分的变化，4和12周。次要结果测量是为了评估认知症状的改善(执行功能，注意,和记忆）在24周时使用NIMHANS（国家心理健康和神经科学研究所）认知电池的子测试。使用不良事件报告表评估副作用。注意评分(p=.023)显示在研究结束时接受800mgL-肌肽的患者中的显著差异。研究完成时，两组的阴性症状没有显着差异。800mg的L-肌肽剂量可能是增强精神分裂症执行功能的有希望的药物。
